AZILECT as First-line Adjunct Therapy

AZILECT decreased "off" time up to 29% when added to levodopa in PRESTO, a large-scale clinical trial.1,2

  • American Academy of Neurology (AAN) practice guidelines recommend that rasagiline should be offered to reduce "off" time.3*
  • Generally well tolerated with a low discontinuation rate due to adverse events (9% for 0.5 mg and 7% for 1 mg vs 6% for placebo).1
  • Tolerability in elderly patients.4
  • Covered or preferred on formulary for majority of commercial and Medicare Part D health plans.

Add once-daily AZILECT at initial signs of wearing off: 0.5 or 1mg/day.2†

The recommended initial dose for adjunct therapy is 0.5 mg administered once daily. If a sufficient clinical response is not achieved, the dose may be increased to 1 mg administered once daily.

Learn more about PRESTO & LARGO

*The American Academy of Neurology does not endorse any specific product for the treatment of PD or its manufacturer.

Please see important safety information and complete prescribing information. 

Learn more about the tolerability of AZILECT.

REFERENCES
1. AZILECT Prescribing Information.
2. The Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005;62:241-248.
3. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.
4. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I; Parkinson Study Group. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427-1429.


 

AZL101023773/101250

 

AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s Disease (PD) as initial monotherapy and as adjunct therapy to levodopa.

IMPORTANT SAFETY INFORMATION ABOUT AZILECT

Azilect is contraindicated with meperidine; the analgesics tramadol, methadone, and propoxyphene; the antitussive agent dextromethorphan; as well as St. John’s wort and cyclobenzaprine. Azilect is also contraindicated with other MAOIs.

In general, the combination of Azilect and antidepressants should be avoided. Caution should be used when giving Azilect concurrently with CYP1A2 inhibitors such as ciprofloxacin. Patients with moderate to severe hepatic impairment should not take Azilect. The daily dose of Azilect should not exceed 1 mg because of the risks associated with nonselective inhibition of MAO. PD patients are advised to monitor for melanoma frequently and see a dermatologist on a regular basis.

The most common side effects as monotherapy include: flu syndrome, arthralgia, depression, and dyspepsia; and as adjunct to levodopa therapy include: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

AZL101023762/101241